ZA202001285B - Antigen-binding proteins targeting shared antigens - Google Patents

Antigen-binding proteins targeting shared antigens

Info

Publication number
ZA202001285B
ZA202001285B ZA2020/01285A ZA202001285A ZA202001285B ZA 202001285 B ZA202001285 B ZA 202001285B ZA 2020/01285 A ZA2020/01285 A ZA 2020/01285A ZA 202001285 A ZA202001285 A ZA 202001285A ZA 202001285 B ZA202001285 B ZA 202001285B
Authority
ZA
South Africa
Prior art keywords
antigen
binding proteins
proteins targeting
shared antigens
targeting shared
Prior art date
Application number
ZA2020/01285A
Other languages
English (en)
Inventor
Joshua Michael Francis
Gijsbert Marnix Grotenbreg
Karin Jooss
Wade Blair
Brendan Bulik-Sullivan
Jennifer Busby
Michele Anne Busby
Mojca Skoberne
Roman Yelensky
Original Assignee
Gritstone Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gritstone Oncology Inc filed Critical Gritstone Oncology Inc
Publication of ZA202001285B publication Critical patent/ZA202001285B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA2020/01285A 2017-08-18 2020-02-28 Antigen-binding proteins targeting shared antigens ZA202001285B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762547146P 2017-08-18 2017-08-18
US201762581368P 2017-11-03 2017-11-03
PCT/US2018/046997 WO2019036688A1 (en) 2017-08-18 2018-08-17 ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS

Publications (1)

Publication Number Publication Date
ZA202001285B true ZA202001285B (en) 2021-08-25

Family

ID=65362959

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/01285A ZA202001285B (en) 2017-08-18 2020-02-28 Antigen-binding proteins targeting shared antigens

Country Status (12)

Country Link
US (2) US20210147550A1 (enExample)
EP (1) EP3668539A4 (enExample)
JP (1) JP2021500852A (enExample)
KR (2) KR20200084320A (enExample)
CN (1) CN111328288B (enExample)
AU (1) AU2018318303A1 (enExample)
CA (1) CA3072816A1 (enExample)
IL (1) IL272466A (enExample)
MX (2) MX2020001879A (enExample)
SG (1) SG11202001368SA (enExample)
WO (1) WO2019036688A1 (enExample)
ZA (1) ZA202001285B (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
HRP20211754T1 (hr) 2014-12-23 2022-03-04 Immatics Biotechnologies Gmbh Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
US9422547B1 (en) 2015-06-09 2016-08-23 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
KR20250097989A (ko) * 2017-12-28 2025-06-30 그릿스톤 바이오, 인코포레이티드 공통 항원을 표적화하는 항원-결합 단백질
EP3784255B1 (en) * 2018-04-19 2025-09-17 Board of Regents, The University of Texas System T cell receptors with mage-b2 specificity and uses thereof
WO2020037302A1 (en) * 2018-08-17 2020-02-20 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens
CN111138521B (zh) * 2018-11-06 2022-10-28 香雪生命科学技术（广东）有限公司 源自于afp抗原的短肽
CN111138522B (zh) * 2018-11-06 2023-01-24 香雪生命科学技术（广东）有限公司 衍生自afp的肿瘤抗原短肽
GB2596461B (en) * 2019-02-20 2023-09-27 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
EP3941491A4 (en) 2019-03-21 2023-03-29 Gigamune, Inc. ENGINEERED CELLS EXPRESSING ANTIVIRAL T-CELL RECEPTORS AND METHODS OF USE
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
US20200318068A1 (en) * 2019-04-04 2020-10-08 Immatics US, Inc. Use of retinoic acid in t-cell manufacturing
AU2020253491A1 (en) 2019-04-05 2021-10-28 Rootpath Genomics, Inc. Compositions and methods for T-cell receptor gene assembly
WO2020227091A1 (en) * 2019-05-03 2020-11-12 Gigamune, Inc. Engineered cells expressing anti-tumor t cell receptors and methods of use thereof
EP3972992A4 (en) 2019-05-20 2023-07-19 Pandion Operations, Inc. MADCAM TARGETED IMMUNOTLERANCE
EP3760217A1 (en) * 2019-07-01 2021-01-06 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd5 specific t cell receptor cell or gene therapy
EP3997116A1 (en) * 2019-07-09 2022-05-18 Medigene Immunotherapies GmbH Magea10 specific t cell receptors and their use
EP3999107A1 (en) 2019-07-16 2022-05-25 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
CN112300261B (zh) * 2019-07-23 2023-03-17 香雪生命科学技术（广东）有限公司 一种衍生自afp的肿瘤抗原短肽
CN114728179A (zh) * 2019-08-19 2022-07-08 潘迪恩运营公司 利用pd-1激动剂的靶向免疫耐受
WO2021048381A1 (en) * 2019-09-13 2021-03-18 Evaxion Biotech Aps Method for identifying stable mhc binding peptides using mass spectrometry
WO2021076939A1 (en) * 2019-10-18 2021-04-22 Board Of Regents, The University Of Texas System Hla-restricted vcx/y peptides and t cell receptors and use thereof
WO2021092094A1 (en) * 2019-11-04 2021-05-14 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared neoantigens
AU2020384374A1 (en) * 2019-11-15 2022-06-09 Seattle Project Corp. Antigen-binding proteins targeting shared neoantigens
CN112898399A (zh) * 2019-12-03 2021-06-04 香雪生命科学技术（广东）有限公司 源自于afp抗原的短肽
CN115960205A (zh) * 2019-12-13 2023-04-14 南京大户生物科技有限公司 原发性肝癌相关抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用
CN113072636B (zh) * 2020-01-06 2024-05-28 香雪生命科学技术（广东）有限公司 一种识别afp的t细胞受体及其编码序列
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
CN113321725B (zh) * 2020-02-28 2024-06-11 香雪生命科学技术（广东）有限公司 一种识别afp的t细胞受体
CN113321727B (zh) * 2020-02-28 2024-04-09 香雪生命科学技术（广东）有限公司 一种识别afp抗原短肽的t细胞受体及其编码序列
JP2023517889A (ja) * 2020-03-10 2023-04-27 マサチューセッツ インスティテュート オブ テクノロジー ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
CN113493505A (zh) * 2020-03-20 2021-10-12 香雪生命科学技术（广东）有限公司 识别afp抗原的高亲和力tcr
JP2023527293A (ja) * 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
CN116096740A (zh) * 2020-06-09 2023-05-09 得克萨斯州大学系统董事会 经改造t细胞受体和使用方法
JP7391208B2 (ja) 2020-07-08 2023-12-04 エルジー エナジー ソリューション リミテッド バッテリーパック及びそれを含む自動車
WO2022026772A1 (en) * 2020-07-29 2022-02-03 Gritstone Bio, Inc. Engineered multi-specific antibodies and related methods of use and manufacture
CN116472050A (zh) * 2020-09-04 2023-07-21 美国卫生和人力服务部 识别p53中r273c或y220c突变的t细胞受体
MX2023003371A (es) * 2020-09-24 2023-04-26 Medigene Immunotherapies Gmbh Receptores de células t específicos de mage-a3 y su uso.
IL301543A (en) * 2020-09-24 2023-05-01 Medigene Immunotherapies Gmbh Prame specific t cell receptors and uses thereof
WO2022087380A1 (en) * 2020-10-23 2022-04-28 Rootpath Genomics, Inc. Compositions and methods for t-cell receptor identification
KR20230104220A (ko) * 2020-11-05 2023-07-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Egfr 항원을 표적화하는 조작된 t 세포 수용체 및 사용 방법
WO2022155503A1 (en) * 2021-01-14 2022-07-21 Gritstone Bio, Inc. Multi-specific antibodies and methods of use
US12053517B2 (en) 2021-01-14 2024-08-06 Gilead Sciences, Inc. HIV vaccines and methods of using
US20240239864A1 (en) * 2021-02-16 2024-07-18 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class i-restricted t cell receptors against cd22
JP2024509910A (ja) 2021-03-09 2024-03-05 シーディアール－ライフ・アクチェンゲゼルシャフト Ｍａｇｅ－ａ４ペプチド－ｍｈｃ抗原結合タンパク質
EP4304725A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
EP4313139A4 (en) * 2021-03-29 2025-07-02 Univ Texas MODIFIED T-CELL PEPTIDES AND RECEPTORS TARGETING SARS-CoV-2 ANTIGENS AND METHODS OF USE
WO2022216574A1 (en) * 2021-04-05 2022-10-13 Janssen Biotech, Inc. Calr and jak2 t-cell receptors
WO2022229966A1 (en) 2021-04-29 2022-11-03 Yeda Research And Development Co. Ltd. T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same
EP4091627A1 (en) * 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
WO2022251283A1 (en) * 2021-05-25 2022-12-01 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ras mutations and uses thereof
US20250073323A1 (en) * 2021-08-06 2025-03-06 Anyadi, Llc Process for producing personalized cancer immunotherapy
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
JP2024539273A (ja) * 2021-10-25 2024-10-28 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｍａｇｅ－ａ４抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法
US20240415886A1 (en) * 2021-10-29 2024-12-19 Yafei Hou T cell receptor recognizing r175h mutation in p53 and its application
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
CA3244259A1 (en) * 2022-02-23 2023-08-31 Aloe Therapeutics Inc Compositions and methods for modulating the immune system
NL2031118B1 (en) * 2022-03-01 2023-09-07 Academisch Ziekenhuis Leiden T cell receptors directed against transcription factor wt1 and uses thereof
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
CN117264043B (zh) * 2022-06-14 2024-05-10 上海镔铁生物科技有限责任公司 靶向kras g12v突变多肽的t细胞受体及其用途
KR20250067130A (ko) 2022-09-14 2025-05-14 씨디알-라이프 아게 Mage-a4 펩티드 이중 t 세포 연결체
CA3268204A1 (en) * 2022-10-05 2024-04-11 Tscan Therapeutics Inc MAGEA1 IMMUNOGENEOUS PEPTIDES, MAGEA1 IMMUNOGENEOUS PEPTIDE-BINDING PROTEINS, AND THEIR USES
CN116158405B (zh) * 2023-01-30 2024-04-26 西北农林科技大学 一种提高奶山羊后代母羔率的方法
WO2025064738A1 (en) * 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025093596A2 (en) * 2023-10-30 2025-05-08 T-Knife Gmbh Antigen recognizing construct capable of binding to a preferentially expressed antigen in melanoma (prame) peptide and a t cell receptor (tcr) having antigenic specificity for prame as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit
CN118256604B (zh) * 2024-04-16 2024-11-19 华中科技大学 一种利用人工抗原呈递细胞进行免疫原性肿瘤新抗原筛选与鉴定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
CA2476625A1 (en) * 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
EP2356270B1 (en) * 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
SI2755997T1 (sl) * 2011-09-15 2018-11-30 The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage
WO2013130814A1 (en) * 2012-02-29 2013-09-06 Ambrx, Inc. Novel prodrug containing molecule compostions and their uses
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CN107921127B (zh) * 2015-05-22 2022-04-08 纪念斯隆-凯特琳癌症中心 对于prame肽具有特异性的t细胞受体样抗体
GB201520559D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017124001A2 (en) * 2016-01-14 2017-07-20 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for foxp3-derived peptides

Also Published As

Publication number Publication date
MX2020001879A (es) 2020-07-29
SG11202001368SA (en) 2020-03-30
WO2019036688A1 (en) 2019-02-21
CN111328288A (zh) 2020-06-23
EP3668539A1 (en) 2020-06-24
EP3668539A4 (en) 2021-08-18
KR20200084320A (ko) 2020-07-10
AU2018318303A1 (en) 2020-04-09
JP2021500852A (ja) 2021-01-14
US20230382997A1 (en) 2023-11-30
CA3072816A1 (en) 2019-02-21
IL272466A (en) 2020-03-31
CN111328288B (zh) 2025-11-07
KR20250040097A (ko) 2025-03-21
MX2025011582A (es) 2025-11-03
US20210147550A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
IL275547A (en) Antigen-binding proteins target co-antigens
ZA202001285B (en) Antigen-binding proteins targeting shared antigens
IL278864A (en) Common antigens
IL268517A (en) Anti-tigit antibodies
ZA201905966B (en) Anti-lag3 antibodies
IL267797B1 (en) Anti-gpc3 antibody
SG11202000660QA (en) Anti-tigit antibodies
LT3625259T (lt) Anti-sirpalfa antikūnai
ZA202002141B (en) Anti-transthyretin antibodies
GB201709808D0 (en) Antibodies
ZA201900483B (en) Anti-cd19 antibody formulations
SG10201914130VA (en) GARP-TGF-β ANTIBODIES
GB201710835D0 (en) ROR1 Antibodies
EP3590964A4 (en) IMPROVED MONOCLONAL ANTI-VEGFR-2 ANTIBODY
ZA202103456B (en) Anti-alpha-synuclein antibodies
GB201720970D0 (en) Antibodies
IL273529A (en) Anti-PACAP antibody
IL271067A (en) Anti-trkb antibodies
SG11202009267QA (en) Anti-vegfr-2 antibody
GB201711785D0 (en) Antibodies
IL282030A (en) Antibodies to EPN1
HK40034654A (en) Antigen-binding proteins targeting shared antigens
GB201511196D0 (en) Monoclonal antibodies
HK40054691A (en) Antigen-binding proteins targeting shared antigens
HK40039583A (en) Antigen-bindingproteins targeting shared antigens